• 1:中华医学会心血管病学分会结构性心脏病学组
• 2:中国医师协会心血管内科医师分会结构性心脏病专业委员会

摘要(Abstract)：

<正>经皮肺动脉瓣置入术(percutaneous pulmonary valve implantation,PPVI)是最早应用于临床的经皮瓣膜置换技术[1],主要用于右心室流出道(right ventricular outflow tract,RVOT)重建术后并发右心室流出道功能不全(right ventricular outflow tract dysfunction,RVOTD)的患者。截至2016年6月,全球已完成约10 000例PPVI,美国多家学会近期联合发布了PPVI的操作者和机构要求的专家建议[2]。

关键词(KeyWords)： 经皮肺动脉瓣置入术;专家建议;肺动脉瓣反流;右心室流出道功能不全

Abstract:

Keywords:

基金项目(Foundation):

作者(Author):

参考文献(References)：

• [1]Bonhoeffer P,Boudjemline Y,Saliba Z,et al.Perculaneous replacement of pulmonary valve in a right-ventricle to pulmonaryartery prosthetic conduit with valve dysfunction.Lancet,2000,356(9239):1403-1405.
• [2]Hijazi ZM,Ruiz CE,Zahn E,et al.SCAI/AATS/ACC/STSOperator and Institutional Requirements for Transcatheter Valve Repair and Replacement,Part III:Pulmonic Valve.J Am Coll Cardiol,2015,65(23):2556-2563.
• [3]周达新,潘文志,管丽华,等.经皮肺动脉瓣置入二例报道.中国介入心脏病杂志,2013,21(5):332-334.
• [4]Hoffman JI,Kaplan S.The incidence of congenital heart disease.J Am Coll Cardiol,2002,39(12):1890-1900.
• [5]Chaturvedi RR,Redington AN.Pulmonary regurgitation in congenital heart disease.Heart,2007,93(7):880-889.
• [6]Gatzoulis MA,Balaji S,Webber SA,et al.Risk factors for arrhythmia and sudden cardiac death late after repair of tetralogy of Fallot:a multicentre study.Lancet,2000,356(9234):975-981.
• [7]Murphy JG,Gersh BJ,Mair DD,et al.Long-term outcome in patients undergoing surgical repair of tetralogy of fallot.N Engl J Med,1993,329(9):593-599.
• [8]Nollert GD,Dbritz SH,Schmoeckel M,et al.Risk factors for sudden death after repair of tetralogy of Fallot.Ann Thorac Surg,2003,76(6):1901-1905.
• [9]Cheung EW,Wong WH,Cheung YF.Meta-analysis of pulmonary valve replacement after operative repair of tetralogy of fallot.Am J Cardiol,2010,106(4):552-557.
• [10]Müller J,Engelhardt A,Fratz S,et al.Improved exercise performance and quality of life after percutaneous pulmonary valve implantation.Int J Cardiol,2014,173(3):388-392.
• [11]Ansari MM,Cardoso R,Garcia D,et al.Percutaneous pulmonary valve implantation:present status and evolving future.J Am Coll Cardiol,2015,66(20):2246-2255.
• [12]万俊义,陆敏杰,张戈军,等.经皮肺动脉瓣植入术后患者心功能的变化8例分析.中国循环杂志,2016,31(7):683-686.
• [13]潘文志,张蕾,张晓春,等.经皮自膨胀肺动脉瓣植入的初步经验.中国医学前沿杂志(电子版),2016,8(7):65-68.
• [14]Cheatham JP,Hellenbrand WE,Zahn EM,et al.Clinical and hemodynamic outcomes up to 7 years after transcatheter pulmonary valve replacement in the US melody valve investigational device exemption trial.Circulation,2015,131(22):1960-1970.
• [15]Virk SA,Liou K,Chandrakumar D,et al.Percutaneous pulmonary valve implantation:A systematic review of clinical outcomes.Int J Cardiol,2015,201:487-489.
• [16]Warnes CA,Williams RG,Bashore TM,et al.ACC/AHA 2008Guidelines for the management of adults with congenital heart disease:a report of the American College of Cardiology/American Heart Association task force on practice guidelines(writing committee to develop guidelines on the management of adults with congenital heart disease).Circulation,2008,118(23):e714-e833.
• [17]Nishimura RA,Otto CM,Bonow RO,et al;2014 AHA/ACC guideline for the management of patients with valvular heart disease:executive summary:a report of the American College of Cardiology/American Heart Association task force on practice guidelines.J Am Coll Cardiol,2014,63(22):2438-2488.
• [18]Geva T.Indications and timing of pulmonary valve replacement after tetralogy of Fallot repair.Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu,2006:11-22.
• [19]孙仕怀,王琦光.经皮肺动脉瓣置换术新进展.心血管病学进展,2015,36(4):429-432.
• [20]潘文志,周达新,葛均波.经皮肺动脉瓣置入术适应证及手术时机的研究现状.中华心血管病杂志,2016,44(7):639-641.
• [21]Baumgartner H,Bonhoeffer P,De Groot NM,et al.ESC guidelines for the management of grown-up congenital heart disease(new version 2010).Eur Heart J,2010,31(23):2915-2957.
• [22]周勇,陈少萍,徐荣良,等.皮下8字缝合止血技术在结构性心脏病介入术中的应用.介入放射学杂志,2012,21(12):984-986。
• [23]Asoh K,Walsh M,Hickey E,et al.Percutaneous pulmonary valve implantation within bioprosthetic valves.Eur Heart J,2010,31(11):1404-1409.
• [24]Mc Elhinney DB,Hellenbrand WE,Zahn EM,et al.Short-and medium-term outcomes after transcatheter pulmonary valve placement in the expanded multicenter US melody valve trial.Circulation,2010,122(5):507-516.
• [25]Lurz P,Coats L,Khambadkone S,et a1.Percutaneous pulmonary valve implantation:impact of evolving technology and learning curve on clinical outcome.Circulation,2008,117(15):1964-1972.
• [26]Schievano S,Coats L,Migliavacca F,et al.Variations in right ventricular outflow tract morphology following repair of congenital heart disease:Implications for percutaneous pulmonary valve implantation.J Cardiovasc Magn Reson,2007,9(4):687-695.
• [27]Nordmeyer J,Lurz P,Khambadkone S,et al.Pre-stenting with a bare metal stent before percutaneous pulmonary valve implantation:acute and 1-year outcomes.Heart,2011,97(2):118-123.
• [28]Malekzadeh-Milani S,Ladouceur M,Iserin L,et al.Incidence and outcomes of right-sided endocarditis in patients with congenital heart disease after surgical or transcatheter pulmonary valve implantation.J Thorac Cardiovasc Surg,2014,148(5):2253-2259.
• [29]Nishimura RA,Carabello BA,Faxon DP,et al.ACC/AHA 2008Guideline update on valvular heart disease:focused update on infective endocarditis:a report of the American College of Cardiology/American Heart Association task force on practice guidelines endorsed by the Society of Cardiovascular Anesthesiologists,society for Cardiovascular Angiography and Interventions,and Society of Thoracic Surgeons.J Am Coll Cardiol,2008,52(8):676-685.
• [30]Amat-Santos IJ,Ribeiro HB,Urena M,et al.Prosthetic valve endocarditis after transcatheter valve replacement:a systematic review.JACC Cardiovasc Interv,2015,8(2):334-346.